Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299)

🧪 Interventions in This Study

• Letetresgene autoleucel (DRUG)
• Cyclophosphamide (DRUG)
• Fludarabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• City of Hope National Medical Center — Duarte, California
• Stanford Hospital and Clinics — Stanford, California
• Sarah Cannon Research Institute — Denver, Colorado
• Mayo Clinic Jacksonville — Jacksonville, Florida
• University of Chicago — Chicago, Illinois
• University of Iowa College of Medicine — Iowa City, Iowa
• Dana Farber Cancer Institute — Boston, Massachusetts
• Massachusetts General Hospital — Boston, Massachusetts
• University of Michigan Medical Center — Ann Arbor, Michigan
• Minnesota Oncology Hematology — Minneapolis, Minnesota
• Mayo Clinic Rochester — Rochester, Minnesota
• Washington University — St Louis, Missouri
• Memorial Sloan Kettering cancer center — New York, New York
• Duke University Medical Center — Durham, North Carolina
• Ohio State University-Columbus — Columbus, Ohio
• Oregon Health and Science University — Portland, Oregon
• University of Pittsburgh, Hillman Cancer centre — Pittsburgh, Pennsylvania
• Tennessee Oncology — Nashville, Tennessee
• University Of Texas Southwestern Medical Center — Dallas, Texas
• University of Texas Southwestern Medical Center — Dallas, Texas
• University of Utah — Salt Lake City, Utah
• Virginia Commonwealth University — Richmond, Virginia
• Fred Hutchinson Cancer Research Center — Seattle, Washington
• Froedtert Hospital — Milwaukee, Wisconsin
• CIUSSS de L'Est-De-Lile-De-Montreal — Montreal, Quebec

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neoplasms

• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Goodyear, Arizona
• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
• Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
• M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California

Explore by condition: All Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.